Pre-term infant growth drug fails in Phase III
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum (Sobi)'s pivotal Phase III study of the enzyme therapy Kiobrina (rhBSSL, recombinant human bile salt stimulated lipase) for improving growth in preterm infants, has failed to meet its primary endpoint, according to top-line data.